Literature DB >> 25698882

C-reactive protein and cardiovascular disease in East asians: a systematic review.

Isao Saito1, Koutatsu Maruyama2, Eri Eguchi3.   

Abstract

Elevated C-reactive protein (CRP) levels are associated with an increased risk of cardiovascular disease (CVD) in Caucasians; however, evidence is lacking for East Asians, who have low CRP levels. PubMed and Google Scholar searches were conducted (1966 through September 2014), and eight prospective studies in East Asian countries (China, Hong Kong, Japan, Korea, Macao, Mongolia, and Taiwan) that documented risk ratios of elevated CRP for CVD were included for meta-analysis with random-effects models. The overall association between CRP levels and stroke was significant in six studies (risk ratio = 1.40 [95% confidence interval {CI}, 1.10-1.77], P = 0.008). The association with ischemic stroke was more evident in subgroup analyses. For coronary heart disease (CHD) and CVD, the risk ratio was 1.75 (95% CI, 0.96-3.19, P = 0.07) and 1.76 (95% CI, 1.29-2.40, P < 0.001), respectively. Although East Asians have low CRP levels, this meta-analysis shows that elevated CRP levels were significantly associated with an increased risk of stroke, primarily ischemic stroke.

Entities:  

Keywords:  C-reactive protein; East Asia; cardiovascular disease; systematic review

Year:  2015        PMID: 25698882      PMCID: PMC4319655          DOI: 10.4137/CMC.S17066

Source DB:  PubMed          Journal:  Clin Med Insights Cardiol        ISSN: 1179-5468


Introduction

The inflammatory hypothesis states that endothelial cell damage promotes atherogenesis, linking the complex inflammatory process with cardiovascular events.1,2 Among several parameters of inflammation, C-reactive protein (CRP) measurements have great benefits from the viewpoints of cost and quality. Considerable evidences, including data from clinical intervention trials, also confirm that CRP measurements are useful for identifying individuals at high risk for cardiovascular disease (CVD).3,4 To date, a meta-analysis has documented strong evidence for adding CRP measurements to the measurement of traditional risk factors for predicting coronary heart disease (CHD). The prediction model that included CRP levels indicated a better fit in comparison with a common model using the Framingham risk score. A US clinical guideline concluded that CRP assessment was beneficial in a clinical setting for detecting high-risk individuals.3 Regardless of such a favorable recommendation, aggregated evidence is lacking for Asian individuals. In particular, East Asian populations have low levels of CRP and lower rates of CHD5,6 compared with Western populations.7 The meta-analysis included some Asian cohorts, but the overall analysis concealed the Asian characteristics when the data were pooled. The difference in CRP levels among varied ethnic groups was substantial; therefore, it may not be acceptable to apply the findings from most Western countries to Asian individuals.

Methods

Data sources and searches

We searched the PubMed database for prospective cohort studies of CRP and CVD between 1966 and September 2014 with the following MeSH terms: C-reactive protein, cohort studies, cardiovascular diseases, and Far East. Publications were limited to those written in English. We also examined recent articles published in 2014 from a search of Google Scholar (n = 270).

Study selection

Inclusion criteria for this analysis were as follows: (1) cohort study, including nested case–control study, (2) community-based study in East Asian countries (China, Hong Kong, Japan, Korea, Macao, Mongolia, and Taiwan), and (3) study to estimate the association between CRP and CVD outcomes in adults, defined as incidence or mortality with long-term follow-up. All studies were required to measure standardized CRP by immunoassay. We excluded studies carried out in clinical settings to evaluate the prognosis of diseases or the effect of medications and studies that were conducted with Asian immigrants in the US or other Western countries.

Data extraction and quality assessment

Three researchers evaluated articles in accordance with the inclusion criteria mentioned above. First, after skimming the title and abstract of articles retrieved from the database search, the researchers initially selected the primary articles. Second, potential articles for meta-analysis were retrieved on the basis of evaluation of the full text of the paper. Quality assessment was carried out based on the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement.8 All the selected articles adequately defined outcomes and mentioned the study design, and each had a sufficient follow-up period.

Data synthesis and analysis

Most studies provided hazard ratios or odds ratios for stroke, CHD, and CVD outcomes grouped in accordance with tertiles, quartiles, or quintiles of CRP distribution after adjustment for established CVD risk factors. Although cut-off points differed among studies, we used the risk ratios published in the articles because they appeared to be similar among homogeneous Asian populations. When studies provided only sex-specific associations, we calculated summarized risk ratios that combined both sexes using the fixed-effect model in each study. We calculated the I2 statistics to evaluate the statistical heterogeneity among the studies. We used random-effect meta-regression to evaluate the overall association between CRP and CVD and presented risk ratios and 95% confidence intervals (CIs) stratified by outcomes. The publication bias of selected articles was tested by using funnel plots and the Egger test. All analyses were conducted with Review Manager (RevMan) 5.0 software.

Results

Search results and study inclusion

Our searches retrieved 208 PubMed citations and 2 Google Scholar citations. In all, 22 of them met our inclusion criteria without duplicates (Fig. 1). We excluded 14 articles after a more detailed evaluation, and finally, 8 articles were acceptable for the meta-analysis.9–16
Figure 1

Flow of study selection.

The remaining articles were excluded primarily because they described studies that were performed in a clinical setting (n = 91). The aim of studies was not different from this review purpose (n = 85). The study outcomes were not CVD onset or mortality, or the study design was cross-sectional (n = 12). Though two studies met the inclusion criteria, it was difficult to include them in the meta-analysis, because one was conducted only in men17 and another large population study used a different cut-off point for CRP compared with the other studies, and the distribution of CRP and the incidence of stroke were heterogeneous.18 Of the selected articles, 5 were about the Japanese, 1 about the Chinese, 1 about the Taiwanese, and 1 about the Korean population (Table 1). Of these studies, three provided sex-specific risk ratios for CVD, which were combined into a risk ratio for both sexes with a fixed-effects model.
Table 1

A summary of studies in East Asian cohorts included in the analysis.

OUTCOMESTUDYSURVEY YEAR, SAMPLE SIZE, LOCATIONSTUDY DESIGNCONTROLLED VARIABLESENDPOINTRISK RATIOS AND 95% CIS
Stroke
Wakugawa et al, 2006131988n = 2,692JapanCohortAge, SBP, ECG abnormalities, diabetes, BMI, TC, HDL, smoking, alcohol drinking, and physical activity.Incidence3.11 (1.04–9.32) in men and 1.34 (0.61–2.91) in women for ischemic stroke; and 0.68 (0.21–2.26) and 1.74 (0.51–5.85) for hemorrhagic stroke, respectively, grouped in the highest vs the lowest quintiles.
Iso et al, 2009111988–1990n = 39,242JapanNestedAge, BMI, hypertension, hyperlipidemia, smoking, and drinking status.Mortality1.60 (0.90–2.85) in men and 1.07 (0.58–1.97) in women for total stroke; 2.04 (0.95–4.37) and 1.00 (0.39–2.61) for ischemic stroke; and 1.85 (0.40–8.72) and 1.78 (0.61–5.22) for hemorrhagic stroke, respectively, grouped in the highest vs the lowest quartiles.
Jiang et al, 2009161998–2001n = 2,919ChinaCohortAge, sex, SBP, DBP, diabetes, TC, HDL, BMI, and smoking.Incidence1.58 (1.08–2.31) of CRP >2.0 mg/dl for total stroke in both sexes.
Chen et al, 2009151994–1995n = 3,602TaiwanNestedAge, sex, waist circumference, TC, history of hypertension, history of diabetes.Incidence2.63 (1.06–6.53) for total stroke in both sexes grouped in the highest vs the lowest tertiles.
Chei et al, 2011101984–2001n = 13,521JapanNestedAge, sex, community, SBP, antihypertensive medication, BMI, smoking, alcohol intake, TC, TG, and GLUIncidence1.49 (0.93–2.41) for total stroke; 1.57 (0.85–2.91) for ischemic stroke; and 1.39 (0.60–3.19) for hemorrhagic stroke in both sexes grouped in the highest vs the lowest quintiles.
Iso et al, 2012121990–1993n = 29,876JapanNestedAge, sex, community, SBP, antihypertensive medication, BMI, smoking, alcohol intake, TC, lipid-lowering medication and GLU.Incidence0.93 (0.71–1.23) for total stroke; 1.19 (0.82–1.73) for ischemic stroke; and 0.70 (0.46–1.04) for hemorrhagic stroke in both sexes, grouped in the highest vs the lowest quartiles.
Coronary heart disease
Arima et al, 200891988n = 2,589JapanCohortAge, sex, SBP, ECG abnormalities, diabetes, BMI, TC, HDL, smoking, alcohol intake, and regular exercise.Incidence2.98 (1.53–5.82) in both sexes grouped in the highest vs the lowest quartiles.
Jiang et al, 2009161998–2001n = 2,919ChinaCohortthe same as the aboveIncidence1.13 (0.70–1.83) of CRP >2.0 mg/dl for coronary heart disease in both sexes.
Iso et al, 2009111988–1990n = 39,242JapanNestedthe same as the aboveMortality3.68 (1.02–13.3) in men and 3.74 (0.91–15.3) in women grouped in the highest vs the lowest quartiles.
Iso et al, 2012121990–1993n = 29,876JapanNestedthe same as the aboveIncidence1.02 (0.58–1.72) in both sexes grouped in the highest vs the lowest quartiles.
Cardiovascular disease
Jiang et al, 2009161998–2001n = 2,919ChinaCohortSame as aboveIncidence1.39 (1.04–1.87) of CRP >2.0 mg/dl for coronary heart disease in both sexes.
Iso et al, 2009111988–1990n = 39,242JapanNestedSame as aboveMortality2.31 (1.49–3.59) in men and 1.69 (1.06–2.68) in women grouped in the highest vs the lowest quartiles.
Sung et al, 2014142002–2009n = 268,803KoreaCohortAge, sex, BMI, smoking, alcohol intake, regular exercise, history of hypertension, history of diabetes, history of coronary heart disease, glucose, LDL, HDL, and SBP.Mortality3.48 (1.71–7.10) in men and 0.92 (0.28–3.00) in women grouped in the highest vs the lowest quartiles.

CRP levels among populations

Figure 2 shows the CRP levels (median/geometric mean) among the populations we included for meta-analysis. Most median levels of CRP were very low (less than 1 mg/L).
Figure 2

CRP levels among selected Asian studies.

CRP and CVDs outcomes

The overall association between elevated CRP levels and stroke was significant using the random-effects model with the six stroke studies (risk ratio = 1.39 [95% CI, 1.09–1.77], P = 0.008) (Fig. 3). We did not find significant heterogeneity of effect among the studies (I2 = 32%, P = 0.19). Only one study measured mortality as an outcome, but the association was unchanged if the study was excluded from the analysis. Regarding CHD, the random-effects association was not significant, with wide CIs, when including four studies (risk ratio = 1.75 [95% CI, 0.96–3.19], P = 0.07). There was significant heterogeneity of effect (I2 = 72%, P = 0.01). The risk ratio for CVD was 1.76 (95% CI, 1.29–2.40, P < 0.001), and we found no heterogeneity of effect (I2 = 49%, P = 0.14) among studies.
Figure 3

Risk ratios for stroke, CHD, and CVD with increased CRP levels.

Of the six stroke studies, four studies that were carried out in Japan provided risk ratios by subtype of stroke (Fig. 4). The subgroup analysis revealed that the overall risk ratio of elevated CRP was increased primarily for ischemic stroke (risk ratio = 1.40 [95% CI, 1.08–1.81], P = 0.01) and was not increased for hemorrhagic stroke (risk ratio = 1.04 [95% CI, 0.66–1.65], P = 0.85), although the heterogeneity of their risk ratios was not significant (I2 = 16.9%, P = 0.27).
Figure 4

Subgroup analysis according to stroke subtypes.

Discussion

Main findings

The meta-analysis confirmed that elevated CRP levels were significantly associated with an increased risk of stroke among East Asian populations, primarily for ischemic stroke. The association with CHD was likely to be the same, though the studies were few, and it did not reach a statistically significant level (P = 0.07). Despite lower average levels of CRP in Asians compared with Caucasians, individuals in the highest quartiles or quintiles of CRP were at increased risk of CVD. Previous meta-analyses among US or European studies reported a strong association of elevated CRP levels with CHD, ischemic stroke, cardiovascular mortality, and death from cancer.4 The results of our systematic review were almost consistent with those in Caucasian populations. Stroke is the most common disease among CVD events in Japan. It is well known that Japan is one of the countries with the highest stroke incidence, mainly because of hypertension and high salt intake, regardless of obesity.6 The explanations associated with frequent incident stroke and traditional risk factors and trends among Japanese adults have been reviewed elsewhere. Moreover, of the six studies we included in the present analysis, four showed risk ratios by stroke subtype, ie, ischemic stroke and hemorrhagic stroke. The association of CRP was more evident for ischemic stroke and was not apparent for hemorrhagic stroke. The findings implied that increased CRP levels are linked with atherosclerosis and thrombosis that are closely related to obesity and the metabolic syndrome.1

Ethnic differences in CRP levels and cut-off points

When compared with previous findings from various studies, the level of CRP in Asian populations was approximately one-third of the median value in Caucasians.5 As shown in Figure 2, it seemed to be true that East Asian individuals had low levels of CRP, and that in most populations, the levels were less than 1 mg/L. CRP levels varied among East Asian populations and were relatively higher in Chinese individuals compared with Korean and Japanese individuals. Some polymorphisms were reported to determine the CRP concentrations in the Chinese population19,20; however, it was unclear why CRP concentrations were higher in Chinese individuals. Although CRP levels in Chinese individuals were still low when compared with those in Caucasians, the heterogeneity among Far East countries might be caused by factors related to genetics, lifestyle, or environmental conditions. The majority of studies in Western countries reported CRP average levels more than 1 mg/L, and the levels varied greatly among ethnic groups. For example, the Women’s Health Study reported that median CRP values in black women (2.96 mg/L) were significantly higher than in Hispanics (2.06 mg/L), whites (2.02 mg/L), and Asians (1.12 mg/L) in the US.21 The Dallas Heart Study also pointed out significant race and gender differences in the population distribution of CRP levels, with the highest median values in black women (3.5 mg/L).22 The Asian studies in the present meta-analysis set up quartile or quintile levels of CRP as cut-off points to evaluate risk ratios for CVD, corresponding with approximately 1 mg/L of CRP. This implied that CRP levels >1.0 mg/L were associated with an increased risk of CVD in the Asian population.18 The Multiethnic Study of Atherosclerosis (MESA) study investigated CRP levels across four ethnic groups living in the US.23 In that study, the median CRP levels of Chinese men and women were 0.80 and 0.99 mg/L, respectively, which were roughly consistent with the baseline data we found in the present study. This fact indicated that CRP levels in Asians who live in the Far East might be essentially equal to those in Asians who live in the US. Therefore, CRP levels were greatly influenced by ethnic background, and the cut-off points to detect high-risk individuals should be considered based on ethnicity.

Potential mechanism

It was established that CRP levels were closely related to obesity in various populations.24,25 This may to a large extent explain the fact that CRP levels in Asians with higher BMI levels were very low in comparison with Caucasians with higher BMI levels. It is considered that adipose tissue in obesity overproduces proinflammatory cytokines, such as tissue necrosis factor (TNF)-α and interleukin (IL)-6, which stimulate hepatic CRP production. Furthermore, TNF-α in adipose tissue also inhibits insulin-stimulated autophosphorylation of the insulin receptor and causes insulin resistance.26 Ouchi et al suggested a mechanism by showing that CRP mRNA is expressed in adipose tissue and is inversely related to adiponectin mRNA expression.27 These mechanisms potentially connect obesity with increased CRP concentrations. Recently, several genomic variants that reflected CRP concentrations were studied across ethnic groups.28,29 The contributions of these genetic variants were not large enough to explain the entire difference thus far, but low CRP concentrations in Asia may be in part a result of the genetic variants.30

Limitations

Although this systematic review demonstrated a significant association between CRP levels and CVD in Asians, several limitations should be noted. First, we cannot exclude a publication bias, because the funnel plot was asymmetrical and cohort studies in Asians were very limited. In particular, evidence was very scant to determine an association with CHD events. Second, the risk ratios in each study were calculated with different cut-off points, which might cause bias in estimating the true risk ratio of elevated CRP. Pooled analysis is potentially essential to determine the cut-off point of CRP for CVD prevention. Third, we did not find a sex-specific effect of CRP, because data were not available to find it in this analysis. Some studies documented a difference in the effect between men and women, and the accumulation of further evidence is desired to look at sex differences. Fourth, although risk ratios derived from various cohort studies were adjusted for established CVD risk factors, we will have to investigate whether adding the measurement of CRP levels is valuable in Asians compared with the established prediction models.31

Conclusion

Although East Asian adults had very low levels of CRP, a meta-analysis confirmed that elevated CRP levels were significantly associated with an increased risk of stroke, primarily ischemic stroke. Although it is unclear whether adding CRP measurements to the measurements of traditional risk factors for predicting CHD is beneficial for Asian individuals, original evidence is urgently needed.
  31 in total

Review 1.  Epidemiological evidence of type 2 diabetes mellitus, metabolic syndrome, and cardiovascular disease in Japan.

Authors:  Isao Saito
Journal:  Circ J       Date:  2012-03-27       Impact factor: 2.993

2.  Gender and C-reactive protein: data from the Multiethnic Study of Atherosclerosis (MESA) cohort.

Authors:  Susan G Lakoski; Mary Cushman; Michael Criqui; Tatjana Rundek; Roger S Blumenthal; Ralph B D'Agostino; David M Herrington
Journal:  Am Heart J       Date:  2006-09       Impact factor: 4.749

3.  The impact of C-reactive protein on risk of stroke, stroke subtypes, and ischemic heart disease in middle-aged Japanese: the Japan public health center-based study.

Authors:  Hiroyasu Iso; Hiroyuki Noda; Ai Ikeda; Kazumasa Yamagishi; Manami Inoue; Motoki Iwasaki; Shoichiro Tsugane
Journal:  J Atheroscler Thromb       Date:  2012-07-11       Impact factor: 4.928

4.  C-reactive protein levels among women of various ethnic groups living in the United States (from the Women's Health Study).

Authors:  Michelle A Albert; Robert J Glynn; Julie Buring; Paul M Ridker
Journal:  Am J Cardiol       Date:  2004-05-15       Impact factor: 2.778

5.  Serum C-reactive protein and risk of cardiovascular events in middle-aged and older chinese population.

Authors:  Shan Jiang; Yuqian Bao; Xuhong Hou; Qichen Fang; Chen Wang; Jiemin Pan; Yuhua Zuo; Wenhong Zhong; Kunsan Xiang; Weiping Jia
Journal:  Am J Cardiol       Date:  2009-04-16       Impact factor: 2.778

Review 6.  C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the U.S. Preventive Services Task Force.

Authors:  David I Buckley; Rongwei Fu; Michele Freeman; Kevin Rogers; Mark Helfand
Journal:  Ann Intern Med       Date:  2009-10-06       Impact factor: 25.391

7.  Large multiethnic Candidate Gene Study for C-reactive protein levels: identification of a novel association at CD36 in African Americans.

Authors:  Jaclyn Ellis; Ethan M Lange; Jin Li; Josee Dupuis; Jens Baumert; Jeremy D Walston; Brendan J Keating; Peter Durda; Ervin R Fox; Cameron D Palmer; Yan A Meng; Taylor Young; Deborah N Farlow; Renate B Schnabel; Carola S Marzi; Emma Larkin; Lisa W Martin; Joshua C Bis; Paul Auer; Vasan S Ramachandran; Stacey B Gabriel; Monte S Willis; James S Pankow; George J Papanicolaou; Jerome I Rotter; Christie M Ballantyne; Myron D Gross; Guillaume Lettre; James G Wilson; Ulrike Peters; Wolfgang Koenig; Russell P Tracy; Susan Redline; Alex P Reiner; Emelia J Benjamin; Leslie A Lange
Journal:  Hum Genet       Date:  2014-03-19       Impact factor: 4.132

8.  Meta-analysis of genome-wide association studies in >80 000 subjects identifies multiple loci for C-reactive protein levels.

Authors:  Abbas Dehghan; Josée Dupuis; Maja Barbalic; Joshua C Bis; Gudny Eiriksdottir; Chen Lu; Niina Pellikka; Henri Wallaschofski; Johannes Kettunen; Peter Henneman; Jens Baumert; David P Strachan; Christian Fuchsberger; Veronique Vitart; James F Wilson; Guillaume Paré; Silvia Naitza; Megan E Rudock; Ida Surakka; Eco J C de Geus; Behrooz Z Alizadeh; Jack Guralnik; Alan Shuldiner; Toshiko Tanaka; Robert Y L Zee; Renate B Schnabel; Vijay Nambi; Maryam Kavousi; Samuli Ripatti; Matthias Nauck; Nicholas L Smith; Albert V Smith; Jouko Sundvall; Paul Scheet; Yongmei Liu; Aimo Ruokonen; Lynda M Rose; Martin G Larson; Ron C Hoogeveen; Nelson B Freimer; Alexander Teumer; Russell P Tracy; Lenore J Launer; Julie E Buring; Jennifer F Yamamoto; Aaron R Folsom; Eric J G Sijbrands; James Pankow; Paul Elliott; John F Keaney; Wei Sun; Antti-Pekka Sarin; João D Fontes; Sunita Badola; Brad C Astor; Albert Hofman; Anneli Pouta; Karl Werdan; Karin H Greiser; Oliver Kuss; Henriette E Meyer zu Schwabedissen; Joachim Thiery; Yalda Jamshidi; Ilja M Nolte; Nicole Soranzo; Timothy D Spector; Henry Völzke; Alexander N Parker; Thor Aspelund; David Bates; Lauren Young; Kim Tsui; David S Siscovick; Xiuqing Guo; Jerome I Rotter; Manuela Uda; David Schlessinger; Igor Rudan; Andrew A Hicks; Brenda W Penninx; Barbara Thorand; Christian Gieger; Joe Coresh; Gonneke Willemsen; Tamara B Harris; Andre G Uitterlinden; Marjo-Riitta Järvelin; Kenneth Rice; Dörte Radke; Veikko Salomaa; Ko Willems van Dijk; Eric Boerwinkle; Ramachandran S Vasan; Luigi Ferrucci; Quince D Gibson; Stefania Bandinelli; Harold Snieder; Dorret I Boomsma; Xiangjun Xiao; Harry Campbell; Caroline Hayward; Peter P Pramstaller; Cornelia M van Duijn; Leena Peltonen; Bruce M Psaty; Vilmundur Gudnason; Paul M Ridker; Georg Homuth; Wolfgang Koenig; Christie M Ballantyne; Jacqueline C M Witteman; Emelia J Benjamin; Markus Perola; Daniel I Chasman
Journal:  Circulation       Date:  2011-02-07       Impact factor: 29.690

9.  C-reactive protein, fibrinogen, and cardiovascular disease prediction.

Authors:  Stephen Kaptoge; Emanuele Di Angelantonio; Lisa Pennells; Angela M Wood; Ian R White; Pei Gao; Matthew Walker; Alexander Thompson; Nadeem Sarwar; Muriel Caslake; Adam S Butterworth; Philippe Amouyel; Gerd Assmann; Stephan J L Bakker; Elizabeth L M Barr; Elizabeth Barrett-Connor; Emelia J Benjamin; Cecilia Björkelund; Hermann Brenner; Eric Brunner; Robert Clarke; Jackie A Cooper; Peter Cremer; Mary Cushman; Gilles R Dagenais; Ralph B D'Agostino; Rachel Dankner; George Davey-Smith; Dorly Deeg; Jacqueline M Dekker; Gunnar Engström; Aaron R Folsom; F Gerry R Fowkes; John Gallacher; J Michael Gaziano; Simona Giampaoli; Richard F Gillum; Albert Hofman; Barbara V Howard; Erik Ingelsson; Hiroyasu Iso; Torben Jørgensen; Stefan Kiechl; Akihiko Kitamura; Yutaka Kiyohara; Wolfgang Koenig; Daan Kromhout; Lewis H Kuller; Debbie A Lawlor; Tom W Meade; Aulikki Nissinen; Børge G Nordestgaard; Altan Onat; Demosthenes B Panagiotakos; Bruce M Psaty; Beatriz Rodriguez; Annika Rosengren; Veikko Salomaa; Jussi Kauhanen; Jukka T Salonen; Jonathan A Shaffer; Steven Shea; Ian Ford; Coen D A Stehouwer; Timo E Strandberg; Robert W Tipping; Alberto Tosetto; Sylvia Wassertheil-Smoller; Patrik Wennberg; Rudi G Westendorp; Peter H Whincup; Lars Wilhelmsen; Mark Woodward; Gordon D O Lowe; Nicholas J Wareham; Kay-Tee Khaw; Naveed Sattar; Chris J Packard; Vilmundur Gudnason; Paul M Ridker; Mark B Pepys; Simon G Thompson; John Danesh
Journal:  N Engl J Med       Date:  2012-10-04       Impact factor: 91.245

10.  Relationship between C-reactive protein and stroke: a large prospective community based study.

Authors:  Yanfang Liu; Jing Wang; Liqun Zhang; Chunxue Wang; Jianwei Wu; Yong Zhou; Xiang Gao; Anxin Wang; Shouling Wu; Xingquan Zhao
Journal:  PLoS One       Date:  2014-09-05       Impact factor: 3.240

View more
  12 in total

1.  Effects of febuxostat on insulin resistance and expression of high-sensitivity C-reactive protein in patients with primary gout.

Authors:  Juan Meng; Yanchun Li; Xiaoxu Yuan; Yuewu Lu
Journal:  Rheumatol Int       Date:  2016-11-23       Impact factor: 2.631

2.  Occupational exposure to diesel engine exhaust and alterations in immune/inflammatory markers: a cross-sectional molecular epidemiology study in China.

Authors:  Bryan A Bassig; Yufei Dai; Roel Vermeulen; Dianzhi Ren; Wei Hu; Huawei Duan; Yong Niu; Jun Xu; Meredith S Shiels; Troy J Kemp; Ligia A Pinto; Wei Fu; Kees Meliefste; Baosen Zhou; Jufang Yang; Meng Ye; Xiaowei Jia; Tao Meng; Jason Y Y Wong; Ping Bin; H Dean Hosgood; Allan Hildesheim; Debra T Silverman; Nathaniel Rothman; Yuxin Zheng; Qing Lan
Journal:  Carcinogenesis       Date:  2017-10-26       Impact factor: 4.944

3.  C-Reactive Protein and Hemogram Parameters for the Non-Sepsis Systemic Inflammatory Response Syndrome and Sepsis: What Do They Mean?

Authors:  Bulent Gucyetmez; Hakan K Atalan
Journal:  PLoS One       Date:  2016-02-10       Impact factor: 3.240

4.  Inflammation, Atherosclerosis and Coronary Artery Disease.

Authors:  Yukihiko Momiyama; Hisashi Adachi; DeLisa Fairweather; Nobukazu Ishizaka; Emi Saita
Journal:  Clin Med Insights Cardiol       Date:  2016-08-28

5.  Serum procalcitonin levels distinguish Gram-negative bacterial sepsis from Gram-positive bacterial and fungal sepsis.

Authors:  Shuhua Li; Hengmo Rong; Qinliang Guo; Yifei Chen; Guqing Zhang; Jiong Yang
Journal:  J Res Med Sci       Date:  2016-06-14       Impact factor: 1.852

Review 6.  Atherosclerotic Cardiovascular Risk in Japan.

Authors:  Shuko Nojiri; Hiroyuki Daida
Journal:  Jpn Clin Med       Date:  2017-06-19

7.  The Effects of Menopausal Hormone Therapy on Serum Level of C-reactive Protein in Postmenopausal Korean Women.

Authors:  Whan Shin; Sung Eun Kim; Jee-Yeon Lee; Jong-Wook Seo; Hye Sun Hyun; Ji Hyun Suh; DooSeok Choi; Byung-Koo Yoon
Journal:  J Menopausal Med       Date:  2019-04-25

8.  C-reactive protein and stroke risk in blacks and whites: The REasons for Geographic And Racial Differences in Stroke cohort.

Authors:  Christina R Evans; D Leann Long; George Howard; Leslie A McClure; Neil A Zakai; Nancy S Jenny; Brett M Kissela; Monika M Safford; Virginia J Howard; Mary Cushman
Journal:  Am Heart J       Date:  2019-08-12       Impact factor: 4.749

9.  Higher High-Sensitivity C Reactive Protein is Associated with Future Premature Ventricular Contraction: a Community Based Prospective Cohort Study.

Authors:  Yue Chen; Shouling Wu; Wenyu Li; Binhao Wang; Xu Han; Yiheng Yang; Xumin Guan; Haixu Yu; Bin Waleed Khalid; Huihua Li; Yunlong Xia
Journal:  Sci Rep       Date:  2018-03-26       Impact factor: 4.379

10.  Systemic inflammation is associated with incident stroke and heart disease in East Asians.

Authors:  Mohd A Karim; Christiana Kartsonaki; Derrick A Bennett; Iona Y Millwood; Michael R Hill; Daniel Avery; Zheng Bian; Huaidong Du; Yu Guo; Yijian Qian; Chan Qu; Iain Turnbull; Dan Schmidt-Valle; Chunmei Wang; Canqing Yu; Jun Lv; Junshi Chen; Robert Clarke; Liming Li; Zhengming Chen; Michael V Holmes; Robin G Walters
Journal:  Sci Rep       Date:  2020-03-27       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.